Abstract
The lysosomal aspartyl protease, cathepsin D, has been suggested to play a role in the metastatic potential of several types of cancer. Cathepsin D is secreted by malignant cells, and is believed to be involved in the breakdown of the extracellular matrix. High levels of active cathepsin D have been found in colon cancer, prostate cancer, uterine cancer and ovarian cancer. Also cathepsin D has recently been associated with the development of Alzheimers disease. Hydroxyethyl isosteres with cyclic tertiary amine have proven to be clinically useful as inhibitors of aspartyl proteases similar to cathepsin D in activity, such as the HIV-1 aspartyl protease. In the present study twenty-eight compounds containing (hydroxyethyl)amine isosteres with cyclic tertiary amines have been synthesized. These compounds show significant activity as cathepsin D inhibitors, many with IC50 values in the nanomolar range. For example, the compounds that contain hydroxyethylamines where the amine is formed from N-piperazine-2-carboxylic acid methyl ester, 4y-bb, show IC50 values ranging from 2.5 to 15 nM.
Keywords: NMR, column chromatography, N-phenylpiperazine, HIV-1 protease, combinatorial library, BOC protecting group
Medicinal Chemistry
Title: New Cathepsin D Inhibitorswith Hydroxyethylamine Isosteres: Preparation and Characterization
Volume: 2 Issue: 1
Author(s): S. E. Hatfield, W. E. Godwin, K. Sayyar, J. F. Lindley, A. W. Green, C. J. Trana, M. S. McConnell and R. M. McConnell
Affiliation:
Keywords: NMR, column chromatography, N-phenylpiperazine, HIV-1 protease, combinatorial library, BOC protecting group
Abstract: The lysosomal aspartyl protease, cathepsin D, has been suggested to play a role in the metastatic potential of several types of cancer. Cathepsin D is secreted by malignant cells, and is believed to be involved in the breakdown of the extracellular matrix. High levels of active cathepsin D have been found in colon cancer, prostate cancer, uterine cancer and ovarian cancer. Also cathepsin D has recently been associated with the development of Alzheimers disease. Hydroxyethyl isosteres with cyclic tertiary amine have proven to be clinically useful as inhibitors of aspartyl proteases similar to cathepsin D in activity, such as the HIV-1 aspartyl protease. In the present study twenty-eight compounds containing (hydroxyethyl)amine isosteres with cyclic tertiary amines have been synthesized. These compounds show significant activity as cathepsin D inhibitors, many with IC50 values in the nanomolar range. For example, the compounds that contain hydroxyethylamines where the amine is formed from N-piperazine-2-carboxylic acid methyl ester, 4y-bb, show IC50 values ranging from 2.5 to 15 nM.
Export Options
About this article
Cite this article as:
Hatfield E. S., Godwin E. W., Sayyar K., Lindley F. J., Green W. A., Trana J. C., McConnell S. M. and McConnell M. R., New Cathepsin D Inhibitorswith Hydroxyethylamine Isosteres: Preparation and Characterization, Medicinal Chemistry 2006; 2 (1) . https://dx.doi.org/10.2174/157340606775197705
DOI https://dx.doi.org/10.2174/157340606775197705 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Subungueal Haemorrhages Following Docetaxel (Taxotere) Treatment
Current Drug Safety The Cross-over of Anticancer Agents with Osteoclast Activities
Current Cancer Therapy Reviews Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer
Current Cancer Drug Targets Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Gallic Acid Improved Amytryptiline Effect in Neuropathic Pain Induced by Partial Sciatic Nerve Ligation (PSNL) in Rats
The Natural Products Journal 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Synthesis of Some Benzothiazole Based Piperazine-Dithiocarbamate Derivatives and Evaluation of Their Anticancer Activities
Letters in Drug Design & Discovery Upregulation of DLX2 Confers a Poor Prognosis in Glioblastoma Patients by Inducing a Proliferative Phenotype
Current Molecular Medicine Vitamin D and Breast Cancer Incidence and Outcome
Anti-Cancer Agents in Medicinal Chemistry Targeting the SUMO E2 Conjugating Enzyme Ubc9 Interaction for Anti-Cancer Drug Design
Anti-Cancer Agents in Medicinal Chemistry Human Endometrial and Ovarian Cancer Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity, Potently Induce Cell Cycle Arrest, and Stimulate Apoptosis
Current Medicinal Chemistry HPV and Therapeutic Vaccines: Where are We in 2010?
Current Cancer Therapy Reviews Using Cytokines to Treat Cervical Intraepithelial and Invasive Neoplasia
Recent Patents on Anti-Cancer Drug Discovery Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Targeting Tumour Metastasis: The Emerging Role of Nanotechnology
Current Medicinal Chemistry